CHRU Nancy - Centre Hospitalier Régional Universitaire de Nancy (Siège social : 29 avenue du Maréchal de Lattre de Tassigny, CO 60034, 54035 NANCY CEDEX
Hôpital Central : 29 Avenue du Maréchal de Lattre de Tassigny, 54035 Nancy
Hôpitaux de Brabois / Enfants : Rue du Morvan, 54500 Vandœuvre-lès-Nancy
Maternité régionale :10 Avenue Dr Heydenreich, 54000 Nancy - France)
Abstract : The chimeric antigen receptor T-cells are a new class of anticancer treatment consisting in genetically modifying autologous or allogenic T-cells to make express a CAR directed against a membrane tumor antigen. In Europe, tisagenlecleucel (KymriahTM) has a marketing authorization for the treatment of relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia in children and young adults and of R/R diffuse large B-cell lymphoma (DLBCL). The marketing authorization for axicabtagene ciloleucel (YescartaTM) is the treatment of DLBCL and primary R/R mediastinal B-cell lymphoma. The two products are autologous T-cells directed against CD19. This collaborative work, part of a series of expert opinion-based work, aims to give practical advice to help centers in selection of patients for commercially available CAR T-cell treatment.
https://www.hal.inserm.fr/inserm-03349011 Contributor : Elizabeth BernardoConnect in order to contact the contributor Submitted on : Monday, September 20, 2021 - 10:59:27 AM Last modification on : Tuesday, May 17, 2022 - 2:20:03 PM Long-term archiving on: : Tuesday, December 21, 2021 - 6:31:41 PM
File
Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed
until : jamais
David Beauvais, Emmanuel Bachy, André Baruchel, Jacques-Olivier Bay, Denis Caillot, et al.. Éligibilité des patients aux cellules CAR-T : avis d’experts proposé par la SFGM-TC. Bulletin du Cancer, John Libbey Eurotext, 2021, 108 (7-8), pp.725-729. ⟨10.1016/j.bulcan.2020.10.017⟩. ⟨inserm-03349011⟩